Secreted Phosphoprotein 1 in Lung Diseases

Authors

Hongli Liu
Cristian Coarfa
Arzoo N Charania
Jennifer L Larson-Casey
Ivan O Rosas
Chao He

Language

English

Publication Date

5-30-2025

Journal

Metabolites

DOI

10.3390/metabo15060365

PMID

40559389

PMCID

PMC12195332

PubMedCentral® Posted Date

5-30-2025

PubMedCentral® Full Text Version

Post-print

Abstract

Secreted phosphoprotein 1 (SPP1), also known as osteopontin (OPN) or early T lymphocyte activation protein 1 (ETA-1), is a multifunctional protein involved in numerous biological processes, including immune modulation, stress response, and tissue remodeling. The role of SPP1 in interstitial lung diseases (ILDs) has become an area of increasing interest, given its elevated expression in various ILDs such as idiopathic pulmonary fibrosis (IPF), connective tissue disease-associated ILD (CTD-ILD), and pneumoconiosis, especially with recent data derived from single-cell RNA sequencing. In addition to ILDs, SPP1 has been implicated in infectious granulomatous lung diseases, lung and pleural malignancies, airway diseases, and COVID-19. In most cases, higher SPP1 levels in serum, bronchoalveolar lavage fluid, or lung tissue carry a poor prognosis. SPP1 is expressed in multiple cells critical for fibrogenesis, including macrophages, epithelial cells, and fibroblasts, and SPP1 has emerged as a potential target for therapeutic interventions. Here, we review the proposed mechanisms by which SPP1 contributes to the development of lung disease, with an emphasis on ILD.

Keywords

SPP1, pulmonary fibrosis, interstitial lung diseases, lung cancer, COPD, asthma

Published Open-Access

yes

Recommended Citation

Liu, Hongli; Coarfa, Cristian; Charania, Arzoo N; et al., "Secreted Phosphoprotein 1 in Lung Diseases" (2025). Faculty and Staff Publications. 4747.
https://digitalcommons.library.tmc.edu/baylor_docs/4747